{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:36:27Z","timestamp":1771842987720,"version":"3.50.1"},"reference-count":74,"publisher":"Informa UK Limited","issue":"15","funder":[{"name":"European Union\u2019s Seventh Framework Programme for research"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Microbiol."],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.2217\/fmb-2018-0194","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T15:27:37Z","timestamp":1543591657000},"page":"1683-1692","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":17,"title":["Antibiotic-Nanomedicines: Facing the Challenge of Effective Treatment of Antibiotic-Resistant Respiratory Tract Infections"],"prefix":"10.1080","volume":"13","author":[{"given":"Jeffrey AS","family":"Ritsema","sequence":"first","affiliation":[{"name":"Department of Pharmaceutics,Utrecht Institute for Pharmaceutical Sciences,Utrecht University,\rUtrecht,\rThe Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hessel van","family":"der Weide","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology & Infectious Diseases,Erasmus University Medical Center Rotterdam (Erasmus MC),\rRotterdam,\rThe Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne M","family":"te Welscher","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics,Utrecht Institute for Pharmaceutical Sciences,Utrecht University,\rUtrecht,\rThe Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wil HF","family":"Goessens","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology & Infectious Diseases,Erasmus University Medical Center Rotterdam (Erasmus MC),\rRotterdam,\rThe Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cornelus F","family":"van Nostrum","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics,Utrecht Institute for Pharmaceutical Sciences,Utrecht University,\rUtrecht,\rThe Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert","family":"Storm","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics,Utrecht Institute for Pharmaceutical Sciences,Utrecht University,\rUtrecht,\rThe Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irma AJM","family":"Bakker-Woudenberg","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology & Infectious Diseases,Erasmus University Medical Center Rotterdam (Erasmus MC),\rRotterdam,\rThe Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P","family":"Hays","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology & Infectious Diseases,Erasmus University Medical Center Rotterdam (Erasmus MC),\rRotterdam,\rThe Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"key":"e_1_3_2_3_1","unstructured":"Geneva WHO . Global Health Estimates 2016: Burden of disease by Cause Age Sex by Country and by Region 2000\u20132016 ( 2016 ). www.who.int\/healthinfo\/global_burden_disease\/GHE2016_Deaths_Global_2000_2016.xls?ua=1"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)60692-4"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.79.3.225"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00058-05"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMopv0910749"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00016-10"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/485439a"},{"key":"e_1_3_2_10_1","unstructured":"Council of the European Union . Council conclusions on the impact of antimicrobial resistance in the human health sector and in the veterinary sector \u2013 a \u2018One Health\u2019 perspective. C 211\/2 ( 2012 ). www.consilium.europa.eu\/uedocs\/cms_data\/docs\/pressdata\/en\/lsa\/131126.pdf"},{"key":"e_1_3_2_11_1","unstructured":"United Nations . Draft political declaration of the high-level meeting of the General Assembly on antimicrobial resistance16\u201316108(E) ( 2016 ). www.un.org\/pga\/71\/wp-content\/uploads\/sites\/40\/2016\/09\/DGACM_GAEAD_ESCAB-AMR-Draft-Political-Declaration-1616108E.pdf"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku346"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2010.00134"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3975"},{"key":"e_1_3_2_15_1","unstructured":"Pew Charitable Trusts . Antibiotics currently in global clinical development ( 2018 ). www.pewtrusts.org\/es\/research-and-analysis\/data-visualizations\/2014\/antibiotics-currently-in-clinical-development"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/02713680590968637"},{"issue":"2","key":"e_1_3_2_17_1","first-page":"182","article-title":"The pleuromutilin antibiotics: a new class for human use","volume":"11","author":"Novak R","year":"2010","unstructured":"Novak R , ShlaesDM . The pleuromutilin antibiotics: a new class for human use . Curr. Opin. Investig. Drugs11 ( 2 ), 182 \u2013 191 ( 2010 ).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/24.3.457"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30024-X"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc3995"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2015.997206"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.131532"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.03991.x"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1086\/382690"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2016.1187597"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2007.04.006"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00037-09"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0168-2"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2008.02.011"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2153"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2007.09.005"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/med.20140"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1089\/jamp.2010.0836"},{"key":"e_1_3_2_34_1","article-title":"Inhaled Nano- and microparticles for drug delivery.","volume":"2015","author":"El-Sherbiny I","year":"2015","unstructured":"El-Sherbiny I , ElbazN , Yacoub MagdiH . Inhaled Nano- and microparticles for drug delivery.Glob. Cardiol. Sci. Pract.2015 , 2 ( 2015 ).","journal-title":"Glob. Cardiol. Sci. Pract."},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1513\/pats.200403-023MS"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2017.11.036"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2016.03.002"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp200394t"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S132780"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.09.063"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(00)00339-4"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.2217\/nnm.10.117"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S4937"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/0021-8502(86)90035-2"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666151008124322"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/aps.2017.34"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2011.07.002"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2017.01.011"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv192"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-016-1958-5"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg477"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.colsurfb.2009.04.017"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/0005-2736(91)90201-I"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-3057(03)00057-0"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.27.1.137"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn059"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh518"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2004.10.010"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1601556"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2007.05.062"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.3109\/10717544.2014.882469"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00286"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2009.06.008"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics8010006"},{"key":"e_1_3_2_65_1","unstructured":"Aradigm . Aradigm Announces Top-Line Results from Two Phase 3 Studies Evaluating Pulmaquin for the Chronic Treatment of Non-Cystic Fibrosis Bronchiectasis Patients with Lung Infections with Pseudomonas aeruginosa ( 2016 ). https:\/\/aradigm.gcs-web.com\/news-releases\/news-release-details\/aradigm-announces-top-line-results-two-phase-3-studies"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202230"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0700OC"},{"key":"e_1_3_2_68_1","article-title":"Long-Term Study of Liposomal Amikacin for Inhalation in Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Infection","author":"Konstan M","year":"2015","unstructured":"Konstan M , PresslerT , ClancyJPet al. Long-Term Study of Liposomal Amikacin for Inhalation in Patients With Cystic Fibrosis and Chronic Pseudomonas aeruginosa Infection . Presented at: 29th Annual North American Cystic Fibrosis Conference (NACFC) Denver, CO , 8\u201310 October 2015 .","journal-title":"29th Annual North American Cystic Fibrosis Conference (NACFC)"},{"key":"e_1_3_2_69_1","unstructured":"Insmed . Insmed Announces Additional Data from ALIS (Amikacin Liposome Inhalation Suspension) Phase 3 Clinical Program for Adult Patients with Treatment Refractory NTM Lung Disease Caused by MAC and Reports Progress with Commercial Preparations ( 2018 )."},{"key":"e_1_3_2_70_1","unstructured":"FDA . FDA approves a new antibacterial drug to treat a serious lung disease using a novel pathway to spur innovation ( 2018 ). www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm622048.htm"},{"key":"e_1_3_2_71_1","unstructured":"Axentispharmaag . Axentis Pharma ( 2018 ). www.axentispharma.com\/"},{"key":"e_1_3_2_72_1","unstructured":"FDA . Cumulative List of all Products that have received Orphan Designation ( 2009 ). www.fda.gov\/downloads\/forindustry\/developingproductsforrarediseasesconditions\/howtoapplyfororphanproductdesignation\/ucm162066.xls"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.3109\/08982109909018652"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/41.1.35"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.40.3.665"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.5.1090"}],"container-title":["Future Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fmb-2018-0194","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:40:58Z","timestamp":1719124858000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fmb-2018-0194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":74,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["10.2217\/fmb-2018-0194"],"URL":"https:\/\/doi.org\/10.2217\/fmb-2018-0194","relation":{},"ISSN":["1746-0913","1746-0921"],"issn-type":[{"value":"1746-0913","type":"print"},{"value":"1746-0921","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifmb20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-06-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}